• Thumbnail for Bavarian Nordic
    Bavarian Nordic (redirect from MVA-BN)
    development. MVA-BN is a proprietary technology developed by Bavarian Nordic. It is derived from the Modified vaccinia Ankara virus. MVA-BN is characterized...
    18 KB (1,175 words) - 05:28, 6 September 2024
  • Thumbnail for Smallpox vaccine
    [citation needed] MVA-BN has been approved in the European Union, Canada, and the United States. Clinical trials have found that MVA-BN is safer and just...
    116 KB (12,377 words) - 01:50, 9 September 2024
  • Modified vaccinia Ankara (MVA) is an attenuated (weakened) strain of the vaccinia virus. It is being used as a vaccine (called MVA-BN, brand names: Imvanex...
    16 KB (1,500 words) - 19:42, 13 September 2024
  • Thumbnail for 2023–2024 mpox epidemic
    mpox. Also in June 2024, authorities in the DRC had approved the vaccines MVA-BN (Jynneos) manufactured by Bavarian Nordic, and LC16, manufactured by KM...
    98 KB (7,706 words) - 14:46, 18 September 2024
  • Thumbnail for Mpox
    supplies are limited. All were originally developed to combat smallpox. MVA-BN (marketed as Jynneos, Imvamune or Imvanex) manufactured by Bavarian Nordic...
    79 KB (7,072 words) - 03:53, 14 September 2024
  • Thumbnail for Monkeypox virus
    supplies are limited. All were originally developed to combat smallpox. MVA-BN (marketed as Jynneos, Imvamune or Imvanex) manufactured by Bavarian Nordic...
    32 KB (4,426 words) - 09:04, 4 September 2024
  • Thumbnail for Ebola vaccine
    glycoprotein, while the second component MVA-BN is the Modified Vaccinia Virus Ankara – Bavarian Nordic (MVA-BN) Filo-vector. This product commenced Phase...
    67 KB (6,243 words) - 10:51, 4 September 2024
  • Thumbnail for Timeline of the 2023–2024 mpox epidemic
    Development (USAID). The delivery consisted of 9,980 individual doses of Jynneos MVA-BN vaccine, manufactured by the Danish pharmaceutical company Bavarian Nordic...
    33 KB (3,094 words) - 12:25, 14 September 2024
  • Thumbnail for Viral vector vaccine
    Pharmaceutials and Bavarian Nordic, and utilizes MVA technology in its second vaccine dose of Mvabea (MVA-BN-Filo). Vesicular stomatitis virus (VSV) was introduced...
    32 KB (3,318 words) - 02:25, 16 July 2024
  • Thumbnail for Yellow fever
    Phase I Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18–45...
    111 KB (12,218 words) - 01:39, 14 September 2024